CEO: Wael Fayad
Headquarters: Cambridge, Massachusetts
Investment Date: August 2014
APO Financing: $21,500,000
Trading Venue: Delisted
Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Our unique platform allows us to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases, giving us the potential to positively affect millions of patients who are underserved by current therapeutic alternatives.